ENG/中
老虎證券
行情
产品介绍
Cash Boost账户
美股
美股碎股
港股
A股通
期权
期货
美国国债
定投
固定票息票据
Tiger BOSS Debit Card
基金超市
老虎钱袋子
老虎API平台
Wealth
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
专栏
TigerAI
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務
DTE Energy Company
51.37
0.0000
成交量:
- -
成交額:
- -
市值:
98.93億
市盈率:
8.14
高:
51.37
開:
51.37
低:
51.37
收:
51.37
資料載入中...
總覽
公司
新聞
公告
【大行評級|建銀國際:下調華潤醫藥目標價至5.9港元 下調今明兩年銷售及盈利預測】建銀國際的研究報告指,華潤醫藥2024年下半年銷售額只按年增長5.9%,達到129.1億元,低過該行預期。製造銷售額按年增長7.5%,達到22.5億元,低於該行預期,原因是化學藥品銷售疲軟,這受到API價格波動的影響。分銷銷售額按年增長6%,達到107.3億元,低於該行預期,因為醫療器械業務放緩。零售銷售額按年增長2.1%,達到5.2億元,低於該行預期,因為強勁的DTP(直接面向患者)增長能夠抵銷實體零售業務的疲軟。該行下調對公司今明兩年銷售預測4.9%,降今明兩年的每股盈利預測5.2%,至0.69元及0.77元,將目標價由6.4港元降至5.9港元,維持“跑贏大市”評級。
金融界
·
03-27
鯨觀察|做藥不如搖奶茶?院外零售藥店渠道被寄厚望,但頭部藥房也現經營困境
蓝鲸财经
·
03-19
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/DTP/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DTP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DTP\",,,,,undefined,":{"symbol":"DTP","market":"US","secType":"STK","nameCN":"DTE Energy Company","latestPrice":51.37,"timestamp":1729886400000,"preClose":51.37,"halted":0,"volume":0,"delay":0,"floatShares":191263476,"shares":192581931,"eps":6.308108,"marketStatus":"休市中","change":0,"latestTime":"10-25 16:00:00 EDT","open":51.37,"high":51.37,"low":51.37,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":6.308108,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1748851200000},"marketStatusCode":7,"adr":0,"exchange":"NYSE","adjPreClose":51.37,"dividendRate":0.074898,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DTP\",,,,,undefined,":{"symbol":"DTP","floatShares":191263476,"roa":"2.72%","roe":"10.39%","lyrEps":6.308108,"shares":192581931,"dividePrice":3.8475,"high":51.37,"amplitude":0,"preClose":51.37,"low":51.37,"week52Low":47.05,"pbRate":"0.85","week52High":54.7275,"institutionHeld":0.3036,"latestPrice":51.37,"eps":6.308108,"divideRate":0.074898,"volume":0,"delay":0,"ttmEps":6.308108,"open":51.37,"prevYearClose":51.34},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DTP\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522319633","title":"【大行評級|建銀國際:下調華潤醫藥目標價至5.9港元 下調今明兩年銷售及盈利預測】建銀國際的研究報告指,華潤醫藥2024年下半年銷售額只按年增長5.9%,達到129.1億元,低過該行預期。製造銷售額按年增長7.5%,達到22.5億元,低於該行預期,原因是化學藥品銷售疲軟,這受到API價格波動的影響。分銷銷售額按年增長6%,達到107.3億元,低於該行預期,因為醫療器械業務放緩。零售銷售額按年增長2.1%,達到5.2億元,低於該行預期,因為強勁的DTP(直接面向患者)增長能夠抵銷實體零售業務的疲軟。該行下調對公司今明兩年銷售預測4.9%,降今明兩年的每股盈利預測5.2%,至0.69元及0.77元,將目標價由6.4港元降至5.9港元,維持“跑贏大市”評級。","url":"https://stock-news.laohu8.com/highlight/detail?id=2522319633","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522319633?lang=zh_tw&edition=fundamental","pubTime":"2025-03-27 13:49","pubTimestamp":1743054580,"startTime":"0","endTime":"0","summary":"建银国际的研究报告指,华润医药2024年下半年销售额只按年增长5.9%,达到129.1亿元,低过该行预期。制造销售额按年增长7.5%,达到22.5亿元,低于该行预期,原因是化学药品销售疲软,这受到API价格波动的影响。分销销售额按年增长6%,达到107.3亿元,低于该行预期,因为医疗器械业务放缓。零售销售额按年增长2.1%,达到5.2亿元,低于该行预期,因为强劲的DTP(直接面向患者)增长能够抵销实体零售业务的疲软。该行下调对公司今明两年销售预测4.9%,降今明两年的每股盈利预测5.2%,至0.69元及0.77元,将目标价由6.4港元降至5.9港元,维持“跑赢大市”评级。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/27134949080675.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["159883","DTP","09997","03320","09996"],"gpt_icon":0},{"id":"2520262902","title":"鯨觀察|做藥不如搖奶茶?院外零售藥店渠道被寄厚望,但頭部藥房也現經營困境","url":"https://stock-news.laohu8.com/highlight/detail?id=2520262902","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520262902?lang=zh_tw&edition=fundamental","pubTime":"2025-03-19 19:21","pubTimestamp":1742383279,"startTime":"0","endTime":"0","summary":"蓝鲸新闻3月18日讯 近日,“雪王”蜜雪冰城IPO市值快速突破1500亿元,却引来医药领域羡慕的目光,有医药人自嘲“做药不如做奶茶攒钱”,创新药在国内商业化承压成为业内痛点。院外市场被寄予厚望,不过,药品零售市场整体也已经进入薄利时代,其中头部特药药房,包括圆心科技、思派健康等也陷入长期亏损、毛利率低等经营困境。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/253432","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["06978","00314","BK1161","BK1247","BK1574","DTP"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DTP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2022-11-01","symbol":"DTP","reason":null,"defaultRemindTime":1667309400000,"announcedDate":"2022-10-28","type":"delisting","dateTimestamp":1667275200000},{"market":"US","date":"2022-10-14","symbol":"DTP","amount":0.78125,"defaultRemindTime":1665754200000,"name":"DTE Energy Company","recordDate":"2022-11-01","payableDate":"2022-10-17","currency":"USD","type":"dividend","dateTimestamp":1665720000000},{"market":"US","date":"2022-07-14","symbol":"DTP","amount":0.78125,"defaultRemindTime":1657805400000,"name":"DTE Energy Company","recordDate":"2022-08-01","payableDate":"2022-07-15","currency":"USD","type":"dividend","dateTimestamp":1657771200000},{"market":"US","date":"2022-04-13","symbol":"DTP","amount":0.78125,"defaultRemindTime":1649856600000,"name":"DTE Energy Company","recordDate":"2022-05-01","payableDate":"2022-04-14","currency":"USD","type":"dividend","dateTimestamp":1649822400000},{"market":"US","date":"2022-01-13","symbol":"DTP","amount":0.78125,"defaultRemindTime":1642084200000,"name":"DTE Energy Company","recordDate":"2022-02-01","payableDate":"2022-01-14","currency":"USD","type":"dividend","dateTimestamp":1642050000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DTP\",market:\"US\",,,undefined,":[{"executeDate":"2020-01-14","recordDate":"2020-01-15","paymentDate":"2020-02-01","value":0.78125,"currency":"USD"},{"executeDate":"2020-04-14","recordDate":"2020-04-15","paymentDate":"2020-05-01","value":0.78125,"currency":"USD"},{"executeDate":"2020-07-14","recordDate":"2020-07-15","paymentDate":"2020-08-01","value":0.78125,"currency":"USD"},{"executeDate":"2020-10-14","recordDate":"2020-10-15","paymentDate":"2020-11-01","value":0.78125,"currency":"USD"},{"executeDate":"2021-01-14","recordDate":"2021-01-15","paymentDate":"2021-02-01","value":0.78125,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DTP\",market:\"US\",delay:false,,,undefined,":{}}}